Jyotsana Pandey

Dr. Jyotsana Pandey

University of Alabama at Birmingham
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
OPOm Prakash Singh Patel
Om Prakash Singh Patel
AMAkansha Mishra
Akansha Mishra
RMRanjani Maurya
Ranjani Maurya
DSDeepika Saini
Deepika Saini
JPJyotsana Pandey
Jyotsana Pandey
PYPrem P. Yadav
Prem P. Yadav

29 May 2015 in Free Radical Research
Verified
Journal Article
Closed access
NJN. Jaiswal
N. Jaiswal
CMC. K. Maurya
C. K. Maurya
JPJyotsana Pandey
Jyotsana Pandey
ARA. K. Rai
A. K. Rai
ATA. K. Tamrakar
A. K. Tamrakar
High fructose consumption has implicated in insulin resistance and metabolic syndrome. Fructose is a highly lipogenic sugar that has intense metabolic effects in liver. Recent evidences suggest that fructose exposure to other tissues has substantial and profound metabolic consequences predisposing toward chronic conditions such as type 2 diabetes. Since skeletal muscle is the major site for glucose utilization, in the present study we define the effects of fructose exposure on glucose utilization in skeletal muscle cells. Upon fructose exposure, the L6 skeletal muscle cells displayed diminished glucose uptake, glucose transporter type 4 (GLUT4) translocation, and impaired insulin signaling. The exposure to fructose elevated reactive oxygen species (ROS) production in L6 myotubes, accompanied by activation of the stress/inflammation markers c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase 1/2 (ERK1/2), and degradation of inhibitor of NF-κB (IκBα). We found that fructose caused impairment of glucose utilization and insulin signaling through ROS-mediated activation of JNK and ERK1/2 pathways, which was prevented in the presence of antioxidants. In conclusion, our data demonstrate that exposure to fructose induces cell-autonomous oxidative response through ROS production leading to impaired insulin signaling and attenuated glucose utilization in skeletal muscle cells.

1 December 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CMChandan K. Maurya
Chandan K. Maurya
DADeepti Arha
Deepti Arha
ARAmit K. Rai
Amit K. Rai
SKShashi Kant Kumar
Shashi Kant Kumar
JPJyotsana Pandey
Jyotsana Pandey
ATAkhilesh Tamrakar
Akhilesh Tamrakar

1 October 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DSDeepak K. Sharma
Deepak K. Sharma
JPJyotsana Pandey
Jyotsana Pandey
ATAkhilesh K. Tamrakar
Akhilesh K. Tamrakar
DMDebaraj Mukherjee
Debaraj Mukherjee

4 May 2019 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
JPJyotsana Pandey
Jyotsana Pandey
ATAkhilesh Tamrakar
Akhilesh Tamrakar
Introduction: The sodium-glucose linked transporter 2 (SGLT2) is ascribed to target renal tubular glucose re-absorption, and its inhibition has been proved to induce glucosuria which improves the glycemic index. Accordingly, SGLT2 inhibitors have found to be the promising class of antidiabetic agents for the management of type 2 diabetes mellitus. A large number of SGLT2 inhibitors have developed through structural modification and investigated for their ability to selectivity inhibit SGLT2 transporters with better bioavailability. Areas covered: This review comprises a summary of patent applications (2013 - 2018) of SGLT2 inhibitors with focus on chemical structural advancement and therapeutic potentials in the management of diabetes and related disorders. Expert opinion: SGLT2 inhibitors exert multiple metabolic benefits, including reduced glycated hemoglobin (HbA1c), improved glycemic control (fasting and postprandial), reduced body weight, reduced systolic and diastolic blood pressure and improved HDL cholesterol. Due to the virtue of no interference with insulin action and secretion, their efficacy remains the same even in presence of progressive β-cell failure in type 2 diabetes. Additionally, few members of this class have been reported to exhibit cardioprotective, renoprotective and anticancer activity. However, more study on the long term outcomes in patients taking SGLT2 inhibitors is warranted.

4 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AMAkansha Mishra
Akansha Mishra
KSKhushbu Sharma
Khushbu Sharma
JPJyotsana Pandey
Jyotsana Pandey
KDKapil Dev
Kapil Dev
SKsleman kadan
sleman kadan
RMRakesh Maurya
Rakesh Maurya
The stem of Tinospora cordifolia has been traditionally used in traditional Indian systems of medicine for blood sugar control, without the knowledge of the underlying mechanism and chemical constitution responsible for the observed anti-diabetic effect. In the present study, Tinosporaside, a diterpenoid isolated from the stem of T. cordifolia, was investigated for its effects on glucose utilization in skeletal muscle cells, which was followed by determining the anti-hyperglycemic efficacy in our diabetic db/db mice model. We found that tinosporaside augmented glucose uptake by increasing the translocation of GLUT4 to the plasma membrane in L6 myotubes, upon prolonged exposure for 16 h. Moreover, tinosporaside treatment significantly increased the phosphorylation of protein kinase B/AKT (Ser-473) and 5′ AMP-activated protein kinase (AMPK, Thr-172). These effects were abolished in the presence of the wortmannin and compound C. Administration of tinosporaside to db/db mice improved glucose tolerance and peripheral insulin sensitivity associated with increased gene expression and phosphorylation of the markers of phosphoinositide 3-kinases (PI3Ks) and AMPK signaling in skeletal muscle tissue. The findings revealed that tinosporaside exerted its antidiabetic efficacy by enhancing the rate of glucose utilization in skeletal muscle, mediated by PI3K- and AMPK-dependent signaling mechanisms.